Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOBT IO Biotech	$1.74 -1.7%	$1.70	$0.66 ▼ $2.79	N/A	0.44	8.63 million shs	1.45 million shs
KLTO Klotho Neurosciences	$0.75 +10.1%	$1.13	$0.11 ▼ $3.91	$45.96M	10.9	1.58 million shs	1.42 million shs
KYTX Kyverna Therapeutics	$3.85 +7.5%	$3.46	$1.78 ▼ $8.78	$166.50M	3.05	259,877 shs	632,566 shs
MCRB Seres Therapeutics	$19.44 +6.1%	$12.90	$6.53 ▼ $26.40	$170.19M	2.9	130,348 shs	167,878 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOBT IO Biotech	0.00%	-19.44%	-9.84%	+43.80%	+10.13%
KLTO Klotho Neurosciences	0.00%	-12.94%	-41.04%	+289.39%	+74,879,900.00%
KYTX Kyverna Therapeutics	0.00%	+9.69%	-9.20%	+69.60%	-54.17%
MCRB Seres Therapeutics	0.00%	+16.48%	+45.07%	+153.46%	+11.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IOBT IO Biotech	3.3139 of 5 stars	3.7	3.0	0.0	0.0	3.2	2.5	0.6
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	2.7165 of 5 stars	3.6	2.0	0.0	0.0	3.0	1.7	0.6
MCRB Seres Therapeutics	3.2487 of 5 stars	2.9	1.0	0.0	4.6	2.7	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOBT IO Biotech	3.33	Buy	$8.67	398.08% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A
KYTX Kyverna Therapeutics	3.14	Buy	$15.60	305.19% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	278.94% Upside

Current Analyst Ratings Breakdown

Latest KLTO, KYTX, IOBT, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.17 per share	N/A
KYTX Kyverna Therapeutics	$7.03M	23.69	N/A	N/A	$4.26 per share	0.90
MCRB Seres Therapeutics	$126.32M	1.35	N/A	N/A	$3.76 per share	5.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	11/11/2025 (Estimated)
KLTO Klotho Neurosciences	-$6.15M	-$0.45	N/A	∞	N/A	N/A	-325.88%	-242.15%	N/A
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	N/A
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A

Latest KLTO, KYTX, IOBT, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2025	Q2 2025	KLTO Klotho Neurosciences	N/A	-$0.12	N/A	-$0.12	N/A	N/A
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOBT IO Biotech	4.22	1.96	2.32
KLTO Klotho Neurosciences	N/A	135.73	0.29
KYTX Kyverna Therapeutics	N/A	5.39	5.39
MCRB Seres Therapeutics	N/A	1.57	1.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOBT IO Biotech	54.76%
KLTO Klotho Neurosciences	20.07%
KYTX Kyverna Therapeutics	18.08%
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
IOBT IO Biotech	4.80%
KLTO Klotho Neurosciences	26.70%
KYTX Kyverna Therapeutics	22.00%
MCRB Seres Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOBT IO Biotech	30	N/A	N/A	Not Optionable
KLTO Klotho Neurosciences	N/A	61.37 million	44.99 million	N/A
KYTX Kyverna Therapeutics	96	43.25 million	33.73 million	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable

KLTO, KYTX, IOBT, and MCRB Headlines

Recent News About These Companies

Seres Therapeutics’ Earnings Call: Progress Amid Challenges

August 16, 2025 | theglobeandmail.com

Seres Therapeutics Reports Q2 Results and Leadership Change

August 8, 2025 | theglobeandmail.com

Seres (MCRB) Q2 Loss Narrows 34%

August 6, 2025 | fool.com

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6, 2025 | globenewswire.com

Seres Therapeutics (MCRB) Expected to Announce Earnings on Wednesday

July 31, 2025 | marketbeat.com

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

July 31, 2025 | seekingalpha.com

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

July 22, 2025 | globenewswire.com

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025 | globenewswire.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

May 23, 2025 | zacks.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

May 16, 2025 | zacks.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript

May 9, 2025 | insidermonkey.com

Chardan Capital Downgrades Seres Therapeutics (MCRB)

May 9, 2025 | msn.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97

May 7, 2025 | msn.com

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Seres Therapeutics Q1 2025 Earnings Preview

May 6, 2025 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%

May 6, 2025 | aaii.comA

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025 | globenewswire.com

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split

April 24, 2025 | bizjournals.com

Seres Therapeutics trading resumes

April 24, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLTO, KYTX, IOBT, and MCRB Company Descriptions

IO Biotech NASDAQ:IOBT

$1.74 -0.03 (-1.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.02 (+1.15%)

As of 08/22/2025 07:54 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Klotho Neurosciences NASDAQ:KLTO

$0.75 +0.07 (+10.12%)

As of 08/22/2025 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Kyverna Therapeutics NASDAQ:KYTX

$3.85 +0.27 (+7.54%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.92 +0.07 (+1.79%)

As of 08/22/2025 07:54 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Seres Therapeutics NASDAQ:MCRB

$19.44 +1.12 (+6.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.39 -0.05 (-0.26%)

As of 08/22/2025 07:56 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time